JOURNAL OF IMMUNOLOGY RESEARCH AND INNOVATION
Jan-Dec 2024, VOL. 1, ISSUE 1, pp. 21-23
https://doi.org/10.61577/jiri.2024.100005

RESEAPRO JOURNALS

MINI REVIEW

OPEN ACCESS

Advancing immunotherapy for chronic infections: Exploring a new horizon in medicine

Colen Getahun

Department of Biology, University of Gadjah Mada, Indonesia

ABSTRACT

Chronic infections caused by persistent pathogens pose significant challenges to global health, often leading to prolonged illnesses and resistance to conventional treatments. Immunotherapy, an emerging approach that harnesses the body's immune defenses, offers a promising pathway to tackle these issues. This discussion explores the potential of immunotherapy in addressing chronic infections, focusing on recent advancements, core mechanisms, and existing hurdles. Key therapeutic innovations, such as checkpoint inhibitors, monoclonal antibodies, and CAR-T cell therapies, are at the forefront of this transformative field. These approaches are redefining how chronic infectious diseases can be managed, offering new strategies to enhance the immune system's ability to combat persistent pathogens effectively. As immunotherapy continues to evolve, it holds immense promise for improving outcomes in patients with chronic infections, advancing medical research, and reshaping the landscape of treatment options. This rapidly advancing field inspires renewed optimism in the fight against infectious diseases, paving the way for innovative solutions to some of the most pressing challenges in global health.

KEYWORDS

Immunotherapy; Infections; Epstein-Barr virus; Antibodies; Pathogens

ARTICLE HISTORY

Received 09 August 2024; Revised 18 September 2024; Accepted 02 October 2024

Introduction

Chronic infections are a persistent and pervasive challenge in global health, affecting millions of people worldwide. Diseases such as tuberculosis, hepatitis B, and HIV represent significant burdens due to their ability to evade the immune system and resist conventional treatments [1,2]. These infections not only lead to long-term health complications but also contribute to increased mortality and strain on healthcare resources. With antimicrobial resistance on the rise, the need for innovative therapeutic approaches has never been more pressing [2].

Immunotherapy, a field initially developed for cancer and autoimmune diseases, has emerged as a promising solution for managing chronic infections. This approach focuses on harnessing and enhancing the body's immune system to identify and eliminate pathogens. Recent advancements in immunotherapy, including checkpoint inhibitors, monoclonal antibodies, and CAR-T cell therapy, have opened new possibilities for combating stubborn infections [3,4,5]. This article examines the potential of immunotherapy in addressing chronic infections, exploring its mechanisms, recent breakthroughs, and future directions, while highlighting the challenges that must be overcome to fully realize its benefits.

Mechanisms in addressing chronic infections

Immunotherapy

Immunotherapy enhances the immune system's ability to identify and combat persistent pathogens that evade detection through advanced strategies, such as concealing themselves within host cells or suppressing immune activity. Below are key mechanisms by which immunotherapy targets chronic infections:

Checkpoint inhibitors

Checkpoint inhibitors function by obstructing immune checkpoints—regulatory pathways that pathogens exploit to weaken immune responses. By blocking these pathways, immune cells, particularly T-cells, can recover their capacity to identify and eliminate infected cells [4]. For instance, inhibitors targeting PD-1/PD-L1 pathways have shown promise in revitalizing exhausted T-cells in chronic viral infections like hepatitis B and HIV [6].

Monoclonal antibodies (mAbs)

Monoclonal antibodies are laboratory-engineered molecules designed to bind to specific antigens present on pathogens or infected cells. These antibodies can neutralize pathogens, inhibit their entry into host cells, or flag them for destruction by other components of the immune system. Enhanced monoclonal antibody technologies have improved their effectiveness and safety, making them an important tool in addressing chronic infections [7,8].

CAR-T cell therapy

Chimeric Antigen Receptor (CAR)-T cell therapy involves modifying a patient's T-cells to enable them to recognize and destroy infected cells more effectively. Originally developed for treating cancers, CAR-T cell therapy is now being adapted to combat chronic infections like Epstein-Barr virus (EBV) and cytomegalovirus (CMV) [8,9,10]. Preliminary studies suggest that CAR-T cells can target and eliminate infection reservoirs that are typically shielded from immune responses.

***Correspondence:** Colen Getahun, Department of Biology, University of Gadjah Mada, Indonesia. email: Coleng@ugm.ac.id

RESEAPRO JOURNALS

Therapeutic vaccines

Therapeutic vaccines differ from traditional vaccines in that they aim to stimulate the immune system to fight pathogens in individuals who are already infected. By boosting the body's immune responses, these vaccines can help reduce pathogen loads and improve health outcomes. Promising results have been observed in early-stage research on therapeutic vaccines for diseases like hepatitis B and tuberculosis [10].

Recent breakthroughs in immunotherapy for chronic infections

One of the most significant recent developments in immunotherapy for HBV involves the use of checkpoint inhibitors and therapeutic vaccines. Checkpoint inhibitors help reinvigorate T-cells that have become exhausted due to chronic infection, enabling them to effectively target and destroy virus-infected cells [11]. Therapeutic vaccines, on the other hand, aim to stimulate the immune system to mount a stronger and more sustained response against HBV. These therapies, currently under clinical investigation, show promise in reducing viral loads and achieving functional cures by suppressing the virus to undetectable levels without the need for lifelong antiviral medication [12].

In the battle against HIV, immunotherapy has brought forward innovative strategies such as broadly neutralizing antibodies (bNAbs) and latency-reversing agents. bNAbs are engineered to target diverse strains of the HIV virus, preventing its ability to infect new cells and helping clear the virus from the body. Latency-reversing agents work by activating dormant HIV reservoirs, making the virus visible to the immune system and vulnerable to attack. When used in combination, these therapies could potentially pave the way for a functional cure by eliminating hidden reservoirs of the virus that have long been a barrier to eradication [11,12].

Immunotherapy for TB has focused on host-directed therapies that enhance the body's immune response to the Mycobacterium tuberculosis bacterium. These therapies aim to improve the effectiveness of existing antibiotic regimens by boosting the host's ability to control and eliminate the infection. For example, certain immunomodulatory drugs and cytokine therapies are being explored to enhance macrophage activity, which plays a critical role in containing TB bacteria within granulomas [13]. Such approaches not only improve treatment outcomes but also hold the potential to shorten the duration of TB therapy and mitigate the emergence of drug resistance.

These advancements underscore the versatility of immunotherapy in addressing a spectrum of chronic infections. By targeting the unique challenges posed by each pathogen, immunotherapy offers the potential for more effective, durable, and personalized treatments that go beyond the limitations of conventional approaches [13].

Challenges in implementing immunotherapy for chronic infections

Chronic infections are caused by pathogens that have evolved sophisticated strategies to evade immune system detection. These mechanisms include hiding within host cells, altering antigen presentation, and suppressing immune responses through the release of inhibitory molecules [2]. Developing immunotherapies that can effectively counter these strategies is complex and requires a delicate balance to avoid overstimulating the immune system, which could lead to autoimmune reactions [14,15]. Researchers must continuously innovate to design targeted therapies that enhance immune function without compromising safety.

The high cost of immunotherapy treatments, such as CAR-T cell therapy and monoclonal antibodies, presents a significant barrier to widespread adoption. These therapies require advanced manufacturing techniques, specialized facilities, and skilled personnel, making them financially and logistically challenging, particularly in low- and middle-income countries. These regions often bear the highest burden of chronic infections, further exacerbating health disparities [16]. Addressing this issue requires global collaboration to reduce production costs, scale up manufacturing, and develop infrastructure that can support the equitable distribution of these therapies.

While immunotherapy has shown remarkable potential, it is not without risks. Treatments can sometimes provoke unintended immune responses, such as cytokine release syndrome (CRS), a severe inflammatory reaction, or off-target effects that damage healthy tissues [16]. These adverse events pose significant challenges to the safety and acceptability of immunotherapy. Researchers are working to mitigate these risks by developing methods to monitor and modulate immune responses during treatment, such as incorporating safety switches in CAR-T cell therapies or optimizing dosing regimens for checkpoint inhibitors.

Addressing these challenges is critical to unlocking the full potential of immunotherapy for chronic infections. By overcoming these obstacles, the medical community can pave the way for more effective and accessible treatments, ultimately transforming outcomes for patients worldwide [8].

Future directions

To address these challenges and fully realize the potential of immunotherapy in treating chronic infections, several key areas need attention:

Combination therapies

Integrating immunotherapy with conventional treatments, such as antibiotics or antiviral drugs, can enhance therapeutic outcomes and reduce the likelihood of resistance. Combining these approaches allows for a multifaceted attack on pathogens, improving treatment efficacy [11].

Personalized medicine

Tailoring immunotherapy to the specific needs of individual patients, based on their genetic makeup and immune profiles, holds the potential to maximize treatment effectiveness while minimizing adverse effects. Advances in precision medicine can guide the development of customized therapeutic strategies.

Cost reduction strategies

Developing more efficient production methods and alternative delivery systems is essential to lowering the costs of immunotherapy. By making these treatments more affordable,

https://doi.org/10.61577/jiri.2024.100005

they can reach a broader population, including those in resource-limited settings [5].

Large-scale clinical trials

Conducting comprehensive clinical trials is critical to evaluating the safety, efficacy, and long-term benefits of immunotherapy in diverse patient populations. Robust trial data can help establish guidelines for widespread adoption and address concerns regarding its use.

Conclusion

Immunotherapy is transforming the management of chronic infections by leveraging the immune system to tackle the obstacles posed by persistent pathogens. Advances in treatments like checkpoint inhibitors, monoclonal antibodies, and CAR-T cell therapies are driving significant progress in this field. By overcoming existing challenges and fostering innovation, immunotherapy has the potential to reshape the landscape of infectious disease treatment, offering renewed hope to countless individuals across the globe.

References

1. Bollard CM, Kuehnle I, Leen A, Rooney CM, Heslop HE. Adoptive immunotherapy for posttransplantation viral infections. Biol Blood Marrow Transplant. 2004;10(3):143-155. https://doi.org/10.1016/j.bbmt.2003.09.017
2. Hemminki O, Dos Santos JM, Hemminki A. Oncolytic viruses for cancer immunotherapy. J Hematol Oncol. 2020;13:1-5. https://doi.org/10.1186/s13045-020-00922-1
3. Einsele H, Löffler J, Kapp M, Rasche L, Mielke S, Grigoleit UG. Immunotherapy for viral and fungal infections. Bone Marrow Transplant. 2015;50(2):51-54. https://doi.org/10.1038/bmt.2015.96
4. Atanley E, van Drunen Littel-van den Hurk S. Future considerations for dendritic cell immunotherapy against chronic viral infections. Expert Rev Clin Immunol. 2014;10(6):801-813. https://doi.org/10.1586/1744666X.2014.907742
5. Chiocca EA, Rabkin SD. Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol Res. 2014;2(4):295-300. https://doi.org/10.1158/2326-6066.CIR-14-0015
6. Saura-Esteller J, De Jong M, King LA, Ensing E, Winograd B, De Gruijl TD, et al. Gamma delta T-cell based cancer immunotherapy: past-present-future. Front Immunol. 2022;13:915837. https://doi.org/10.3389/fimmu.2022.915837
7. Chang AJ, Zhao L, Zhu Z, Boulanger K, Xiao H, Wakefield MR, et al. The past, present and future of immunotherapy for metastatic renal cell carcinoma. Anticancer Res. 2019;39(6):2683-2687. https://doi.org/10.21873/anticanres.13393
8. Tao Z, Li S, Ichim TE, Yang J, Riordan N, Yenugonda V, et al. Cellular immunotherapy of cancer: an overview and future directions. Immunotherapy. 2017;9(7):589-606. https://doi.org/10.2217/imt-2016-0086
9. Finegold I. Allergen immunotherapy: present and future. InAllergy & Asthma Proceedings; 2007. https://doi.org/10.2500/aap.2007.28.2971
10. Khan M, Maker AV, Jain S. The evolution of cancer immunotherapy. Vaccines. 2021;9(6):614. https://doi.org/10.3390/vaccines9060614
11. Wang X, Fan S, Pan H, Chen W, Wang H. Cancer immunotherapy for metastasis: past, present and future. Brief Funct Genom. 2019;18(2):140-146. https://doi.org/10.1093/bfgp/ely022
12. Boettcher AN, Usman A, Morgans A, VanderWeele DJ, Sosman J, Wu JD. Past, current, and future of immunotherapies for prostate cancer. Front Oncol. 2019;9:884. https://doi.org/10.3389/fonc.2019.00884
13. Dhar R, Seethy A, Singh S, Pethusamy K, Srivastava T, Talukdar J, et al. Cancer immunotherapy: Recent advances and challenges. J Cancer Res Ther. 2021;17(4):834-844. https://doi.org/10.4103/jcrt.JCRT_1241_20
14. Cross D, Burmester JK. Gene therapy for cancer treatment: past, present and future. Clin Med Res. 2006;4(3):218-227.
15. Li Y, Wang H. Complement as new immunotherapy target: past, present, and future. InBiologics and Biosimilars; 2022. 341-370p.
16. Modabber F. Leishmaniasis vaccines: past, present and future. Int J Antimicrob Agents. 2010;36:58-61. https://doi.org/10.1016/j.ijantimicag.2010.06.024

https://doi.org/10.61577/jiri.2024.100005